Recently, two phase 3 trials with upadacitinib, an oral JAK‐1 inhibitor, presented significant improvements in mild‐to‐severe CHE in patients with moderate‐to‐severe AD compared to placebo at 16 weeks.9 Here, JAK1 is linked to Alzheimer disease.